4 Healthcare Stock Stories for Prudent Investors

The Medicines Company (NASDAQ:MDCO): Closing price $28.83

The firm reported results on Tuesday for its pivotal Phase 3 clinical trial of cangrelor, in development to prevent platelet activation and aggregation which leads to thrombosis in the acute care setting, including in patients undergoing percutaneous coronary intervention. Subsequent to the recommendation of the trial’s Data Safety Monitoring Board in July, to continue the protocol as planned, the CHAMPIONPHOENIX trial finalized enrollment in October. Folloiwng a successful data lock, the data analysis indicated that the protocol defined primary composite efficacy endpoint of death, myocardial infarction, ischemia driven revascularization, and stent thrombosis at 48 hours was met. Cangrelor showed statistically significant improvement when compared to clopidogrel.